Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06113289 | A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT05190471 | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 48 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06613217 |
| Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia |
| recruiting |
| Phase 1 |
| 35 |
| Pacylex PharmaceuticalsINDUSTRY |
| 1 |
| Mar 10, 2025 |
| clinicaltrials |
| NCT04477291 | A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | terminated | Phase 1 | 45 | Aptose Biosciences Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06865352 | Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 15 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT02834390 | Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 | 7 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04980885 | A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02038777 | A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | completed | Phase 1 | 48 | PfizerINDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06299462 | PTCy and ATG for MSD and MUD Transplants | recruiting | Phase 1 / Phase 2 | 50 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06835140 | CD123-CD16-NK Cells Immunotherapy for AML(CD123-CD16-NK) | recruiting | Phase 1 | 9 | Chunji GaoOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06651866 | Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients | recruiting | Phase 1 | 18 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06737523 | Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML | recruiting | Phase 1 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03027102 | Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia | completed | Phase 1 | 7 | University Health Network, TorontoOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT01743807 | Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia | terminated | Phase 1 | 4 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT04887259 | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | terminated | Phase 1 | 16 | Lava TherapeuticsINDUSTRY | 4 | Jan 27, 2025 | clinicaltrials |
| NCT01261312 | SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 414 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT05601726 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients(ODYSSEY) | recruiting | Phase 1 / Phase 2 | 36 | Advanced BioDesignINDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04623944 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | active not recruiting | Phase 1 | 61 | Nkarta, Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03194685 | Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 97 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06746519 | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 135 | Chen SuningOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02488408 | A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS | completed | Phase 1 / Phase 2 | 122 | BerGenBio ASAINDUSTRY | 4 | Dec 19, 2024 | clinicaltrials |
| NCT06731699 | A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS | recruiting | Phase 1 | 72 | Chengdu FenDi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT04310592 | Natural Killer Cell (CYNK-001) Infusions in Adults with AML(CYNK001AML01) | terminated | Phase 1 | 27 | Celularity IncorporatedINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | terminated | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04282668 | A Study of TAS1440 With ATRA in Subjects With r/r AML | terminated | Phase 1 | 52 | Taiho Oncology, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | recruiting | Phase 1 | 54 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Dec 6, 2024 | clinicaltrials |
| NCT02014558 | Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 265 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Dec 3, 2024 | clinicaltrials |
| NCT03730012 | A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 11 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT04755244 | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | terminated | Phase 1 | 14 | ALX Oncology Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT04079296 | A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 43 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 26, 2024 | clinicaltrials |
| NCT02561455 | Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial | completed | Phase 1 / Phase 2 | 9 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06034275 | Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies | recruiting | Phase 1 | 36 | Vincerx Pharma, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT05266950 | Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Beijing Boren HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06420063 | Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML(BAH244) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03927261 | PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS | active not recruiting | Phase 1 | 88 | Precigen, IncINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT02181660 | Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 24 | Astellas Pharma IncINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05601466 | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT02236013 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 80 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05503134 | Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML(KARMA) | recruiting | Phase 1 / Phase 2 | 20 | Nationwide Children's HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT02610062 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 23 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 1, 2024 | clinicaltrials |
| NCT04207190 | Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | completed | Phase 1 | 78 | Sanjay MohanOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT04714372 | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia | completed | Phase 1 | 9 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT02864290 | A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 43 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Oct 23, 2024 | clinicaltrials |
| NCT02270463 | SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission | terminated | Phase 1 / Phase 2 | 16 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 12, 2025source: clinicaltrials